You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Acyclovir - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for acyclovir and what is the scope of freedom to operate?

Acyclovir is the generic ingredient in seven branded drugs marketed by Actavis Elizabeth, Adaptis, Apotex, Aurobindo Pharma Usa, Cadila, Cadila Pharms Ltd, Carlsbad Technology, Chartwell Molecules, Heritage, Ivax Sub Teva Pharms, Lek Pharm, Mylan, Ranbaxy, Roxane, Strides Pharma, Teva, Teva Pharms, Watson Labs, Yiling, Norvium Bioscience, Alembic, Amneal, Padagis Israel, Taro, Zydus Lifesciences, Bausch, Fera Pharms Llc, Amneal Pharms, Anda Repository, Chartwell Rx, Cipla, Cosette, Fougera Pharms Inc, Glenmark Speclt, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Torrent, Xiromed, Actavis Mid Atlantic, Aurobindo Pharma, Hetero Labs Ltd Iii, Hikma, MSN, Novitium Pharma, Rubicon, Vistapharm Llc, Lnhc, Apotex Inc, Carlsbad, Hetero Labs Ltd V, Square Pharms, Sun Pharm Inds Ltd, Zydus Pharms, Abbvie, Eurohlth Intl Sarl, Apothecon, Chartwell Injectable, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Slate Run Pharma, Teva Parenteral, and Glaxosmithkline, and is included in ninety-nine NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acyclovir has forty-six patent family members in twenty-nine countries.

There are fifty-six drug master file entries for acyclovir. Seventy suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for acyclovir

See drug prices for acyclovir

Drug Sales Revenue Trends for acyclovir

See drug sales revenues for acyclovir

Recent Clinical Trials for acyclovir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jena University HospitalPhase 3
Medical University of South CarolinaPhase 4
TakedaPhase 4

See all acyclovir clinical trials

Generic filers with tentative approvals for ACYCLOVIR
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up200MGCAPSULE;ORAL
⤷  Sign Up⤷  Sign Up800MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up400MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for acyclovir

US Patents and Regulatory Information for acyclovir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms ACYCLOVIR SODIUM acyclovir sodium INJECTABLE;INJECTION 206535-001 Aug 31, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ivax Sub Teva Pharms ACYCLOVIR acyclovir CAPSULE;ORAL 074674-001 Apr 22, 1997 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ivax Sub Teva Pharms ACYCLOVIR acyclovir TABLET;ORAL 074836-001 Apr 22, 1997 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline ZOVIRAX acyclovir sodium INJECTABLE;INJECTION 018603-001 Oct 22, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Torrent ACYCLOVIR acyclovir OINTMENT;TOPICAL 209971-001 Jan 11, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms ACYCLOVIR SODIUM acyclovir sodium INJECTABLE;INJECTION 206606-002 Jun 13, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva ACYCLOVIR acyclovir TABLET;ORAL 074556-003 Apr 22, 1997 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for acyclovir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norvium Bioscience ZOVIRAX acyclovir CAPSULE;ORAL 018828-001 Jan 25, 1985 ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience ZOVIRAX acyclovir TABLET;ORAL 020089-001 Apr 30, 1991 ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience ZOVIRAX acyclovir TABLET;ORAL 020089-002 Apr 30, 1991 ⤷  Sign Up ⤷  Sign Up
Bausch ZOVIRAX acyclovir OINTMENT;TOPICAL 018604-001 Mar 29, 1982 ⤷  Sign Up ⤷  Sign Up
Bausch ZOVIRAX acyclovir CREAM;TOPICAL 021478-001 Dec 30, 2002 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for acyclovir

Country Patent Number Title Estimated Expiration
Hungary E039647 ⤷  Sign Up
South Korea 20090010958 MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES ⤷  Sign Up
South Korea 101335185 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2007110778 ⤷  Sign Up
Croatia P20181103 ⤷  Sign Up
Poland 1998750 ⤷  Sign Up
Montenegro 01180 MUKOZNI BIOADHEZIVNI NOSAČ ZA SPORO OSLOBAĐANJE AKTIVNIH SUPSTANCI (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for acyclovir

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498 10C0038 France ⤷  Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.